Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMPIFLA)

• Drug Name: 6-chloro-N-(3-chlorophenyl)quinazolin-4-amine Drug Info
• Synonyms: 6-chloro-N-(3-chlorophenyl)quinazolin-4-amine; 4-Anilidoquinazoline deriv. 12a; AC1NS5EY; SCHEMBL4355658; BDBM4397

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 5328819
  TTD Drug ID: DMPIFLA

Molecule-Related Drug Atlas

Drug(s) Targeting Epidermal growth factor receptor (EGFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sorafenib	DMS8IFC	Hepatocellular carcinoma	2C12.02	Approved	[2]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[3]
Gefitinib	DM15F0X	Solid tumour/cancer	2A00-2F9Z	Approved	[4]
Erlotinib	DMCMBHA	Non-small-cell lung cancer	2C25.Y	Approved	[5]
Vandetanib	DMRICNP	Solid tumour/cancer	2A00-2F9Z	Approved	[6]
Dacomitinib	DMOH8VY	Non-small-cell lung cancer	2C25.Y	Approved	[7]
BIBW 2992	DMTKD7Q	Non-small-cell lung cancer	2C25.Y	Approved	[8]
SKI-758	DMQ8E9R	Ischemia	8B10-8B11	Approved	[9]
Epidermal growth factor	DMVONE6	Vulnerary	ND56.Z	Approved	[7]
Merimepodib	DM0HS92	Breast cancer	2C60-2C65	Approved	[10]

Drug(s) Targeting Metabotropic glutamate receptor 5 (mGluR5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Afq056	DMMHSLC	Fragile X syndrome	LD55	Phase 2/3	[11]
ADX-48621	DM6GTMD	Parkinson disease	8A00.0	Phase 2/3	[12]
RG-7090	DMX8JYN	Fragile X syndrome	LD55	Phase 2	[13]
STX-107	DMLNKX7	Autism spectrum disorder	6A02	Phase 2	[14]
ADX10059	DMGVKHQ	Anxiety disorder	6B00-6B0Z	Phase 2	[15]
McN3377	DMTCADJ	Fragile X syndrome	LD55	Phase 1/2	[16]
MK-3328	DMW2O5D	Alzheimer disease	8A20	Phase 1	[17]
[3H]fenobam	DMBOXA1	Allodynia	MB40.1	Phase 1	[18]
RG7342	DMIW5NG	Schizophrenia	6A20	Phase 1	[19]
Tetra-hydro-oxazolopyridine derivative 2	DMP65Z4	N. A.	N. A.	Patented	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Epidermal growth factor receptor (EGFR)	TTGKNB4	EGFR_HUMAN	Inhibitor	[1]
Metabotropic glutamate receptor 5 (mGluR5)	TTHS256	GRM5_HUMAN	Inhibitor	[1]

References

• [1] Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6.
• [2] Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
• [3] Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
• [4] Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72.
• [5] Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48.
• [6] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
• [8] Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
• [9] Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
• [10] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [11] Metabolism and disposition of the metabotropic glutamate receptor 5 antagonist (mGluR5) mavoglurant (AFQ056) in healthy subjects. Drug Metab Dispos. 2013 Sep;41(9):1626-41.
• [12] Pipeline of Addex Pharma. Addex Pharma. 2009.
• [13] The challenges of clinical trials in fragile X syndrome. Psychopharmacology (Berl) 2014; 231(6): 1237-1250.
• [14] Social Communication is an Emerging Target for Pharmacotherapy in Autism Spectrum Disorder - A Review of the Literature on Potential Agents. J Can Acad Child Adolesc Psychiatry. 2014 February; 23(1):20-30.
• [15] A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and... Gut. 2009 Sep;58(9):1192-9.
• [16] Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
• [17] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 293).
• [18] Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agon... J Pharmacol Exp Ther. 2005 Nov;315(2):711-21.
• [19] Clinical pipeline report, company report or official report of Roche.
• [20] mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706.